Form 4: SOPHiA GENETICS Officer Receives Equity Grant

SOPHiA GENETICS SA reports a significant equity grant to Chief Medical Officer Philippe Menu, comprising restricted stock units and share options.

Summary

• Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, received a grant of 112,936 ordinary shares via Restricted Stock Units (RSUs) on April 2, 2026.
• Additionally, Mr. Menu was granted a share option to purchase 164,671 ordinary shares at an exercise price of $5.04.
• The RSUs vest over a period, with 25% vesting on April 2, 2027, and the remainder vesting quarterly through April 2, 2030.
• The share option also vests over time, with 25% becoming exercisable on April 2, 2027, and the rest vesting monthly until April 2, 2030.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting standard executive compensation practices rather than significant company performance news.

Positives

• Significant equity grant to a key executive, indicating continued investment in leadership and potential alignment of executive interests with shareholder value.
• The grant of RSUs and share options suggests a long-term incentive structure designed to retain executive talent and encourage sustained company performance.

Risks

• Vesting schedules for both RSUs and share options extend over several years, meaning the full benefit is contingent on continued service and company performance.
• The value of the equity grant is subject to market fluctuations and the future performance of SOPHiA GENETICS SA's stock price.

Future Outlook

The vesting schedules for the RSUs and share options indicate a long-term outlook for executive commitment, with significant portions vesting through April 2030.

Industry Context

StockSavvy.ai notes that equity grants to key executives are a common practice in the biotechnology and healthcare technology sectors, aiming to attract and retain talent in competitive fields. The structure of these grants, with multi-year vesting, aligns with industry standards for long-term incentive alignment.

Stakeholder Impact

• Shareholders: The grants align executive incentives with long-term company performance, potentially benefiting shareholders if the stock price appreciates.
• Employees: May signal a stable leadership team, contributing to employee morale and confidence in the company's direction.
• Management: Reinforces the commitment of key executives to the company's future success.

Next Steps

• Continued service by Philippe Menu through the respective vesting dates to realize the full benefit of the equity grants.

Key Dates

Keywords

SOPHiA GENETICS SA, Form 4, Equity Grant, Restricted Stock Units, Share Option, Philippe Menu, Chief Medical Officer, Insider Transaction, Executive Compensation